布地奈德雾化吸入联合孟鲁司特治疗小儿哮喘急性发作的效果分析

Effect of Budesonide Aerosol Inhalation Combined with Montelukast on Acute Asthma Attack in Children

目的分析布地奈德雾化吸入与孟鲁司特联合治疗方案运用在哮喘急性发作患儿中的临床效果及价值。方法此文方便选取该医院开展药物治疗的70例哮喘急性发作患儿收入研究资料,2016年3月—2018年8月为抽选时间,依据抽签法分组,一组纳入35例,试验组采用布地奈德雾化吸入与孟鲁司特联合治疗方案,对照组采用布地奈德雾化吸入治疗方案,关注两组治疗有效统计率、咳嗽消除用时、憋喘消除用时、湿啰音消除用时、哮鸣音消除用时、药物不良反应统计率,并比对两组治疗之前和治疗一周之后一秒用力呼气容积测定值、呼气流量峰值。结果试验组治疗有效统计率(94.29%)比较对照组相关指标(74.29%)更高,差异有统计学意义(χ^2=5.285,P<0.05);试验组咳嗽消除用时、憋喘消除用时、湿啰音消除用时、哮鸣音消除用时(5.24±2.20)d、(3.10±1.02)d、(4.92±1.30)d、(4.05±1.10)d]比较对照组相关指标(7.80±3.15)d、(5.31±1.80)d、(6.80±2.14)d、(5.79±2.20)d]更短,差异有统计学意义(t=3.941、6.319、4.441、4.185,P<0.05);试验组治疗一周之后一秒用力呼气容积测定值、呼气流量峰值(1.55±0.60)L、(3.40±0.89)L/s]比较治疗之前(0.70±0.21)L,(2.30±0.35)L/s:及对照组相关指标(1.10±0.36)L、(2.81±0.60)L/s]更高,差异有统计学意义(t=7.910、6.804及3.804、3.251);试验组药物不良反应统计率(2.86%)比较对照组相关指标(5.71%),差异无统计学意义(χ^2=0.348,P>0.05)。结论对哮喘急性发作患儿采取布地奈德雾化吸入与孟鲁司特联合治疗方案呈现出较优临床疗效,展示临床治疗优势。

Objective To analyze the clinical effect and value of budesonide inhalation combined with montelukast in children with acute asthma attack. Methods This article included 70 cases of children with acute asthma exacerbation in the hospital for drug treatment. From March 2016 to August 2018, the selection time was convenient divided according to the lottery method. One group was included in 35 cases. The test group used Budesonide aerosol inhalation combined with montelukast treatment, the control group used budesonide aerosol inhalation treatment program, pay attention to the effective statistical rate of treatment, cough elimination time, asthma elimination time, wet voice cancellation time, the wheezing sound elimination time, the statistical rate of adverse drug reactions, and the forced expiratory volume measurement value and the peak expiratory flow rate before and after one week of treatment. Results The effective statistical rate of the treatment group (94.29%) was higher than that of the control group (74.29%). The statistical significance was statistically significant(χ^2=5.285, P<0.05). The test group of cough elimination time and asthma elimination time, wet noise cancellation time, wheezing sound elimination time(5.24±2.20)d,(3.10±1.02)d,(4.92±1.30)d,(4.05±1.10)d:compared with the control group (7.80±3.15)d,(5.31±1.80)d,(6.80±2.14)d,(5.79±2.20)d], showing statistically significant significance(t=3.941, 6.319, 4.441, 4.185, P<0.05);test group forced expiratory volume measurement one second, peak expiratory flow rate after one week of treatment of (1.55±0.60)L,(3.40±0.89)L/s:was compared before treat ment (0.70±0.21)L,(2.30±0.35)L/s:and the control group (1.10±0.36)L,(2.81±0.60)L/s:higher, showing statistically significant significance(t=7.910, 6.804 and 3.804, 3.251);the statistical rate of adverse drug reactions in the experimental group (2.86%) compared with the control group (5.71%), no statistically significant difference between the values(χ^2=0.348,P>0.05). Conclusion The combination of budesonide in-halation and montelukast in the acute exacerbation of asthma presents a superior clinical effect and demonstrates the advan-tages of clinical treatment.